title: Polymorphisms in candidate genes: implications for the current treatment of Parkinson's disease.
abstract: Pharmacological treatment remains the cornerstone of therapy in Parkinson's disease. A number of clinical and genetic factors may influence the therapeutic response and treatment-related complications. Some exploratory studies have suggested that genetic polymorphisms may influence an individual's response to dopaminergic therapy and susceptibility to drug-related complications, such as hallucinations, dyskinesias, motor fluctuations and sudden onset of sleep episodes. This article provides a concise summary and discussion of the potential utility and limitation of studies that have examined the influence of genetic polymorphisms on drug-related response and complications in Parkinson's disease.
authors.affiliation: Population Genetics, Genome Institute of Singapore, Singapore.
authors.forename: Lisa
authors.initials: L
authors.lastname: Skipper
authors.forename: Jian-Jun
authors.initials: JJ
authors.lastname: Liu
authors.forename: Eng-King
authors.initials: EK
authors.lastname: Tan
mesh_terms: D000818:Animals; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D014644:Genetic Variation / Q000235:genetics; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy* / Q000235:genetics*; D011110:Polymorphism, Genetic / Q000235:genetics*
chemical_list: D000978:Antiparkinson Agents